相关实验视频

Updated: Jun 10, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

分子动力学揭示了二叶酸还原酶表面活性降低的抑制剂的多部位结合

Mitsugu Araki¹, Toru Ekimoto², Kazuhiro Takemura^3,4

¹Graduate School of Medicine, Kyoto University, 53 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan.

Journal of the American Chemical Society

|October 12, 2024

概括

药物耐药性来自影响抑制剂结合的蛋白质突变. 这项研究揭示了二酸减少酶 (DHFR) 的多重结合状态,为药物敏感性改变提供了一个新模型.

科学领域:

生物化学
计算生物学
药理学

背景情况:

药物耐药性在医学上是一个重大挑战,通常源于蛋白质结构的改变或突变.
虽然稳定的药物与蛋白质相互作用是已知的,但在原子水平上较不敏感的抑制剂的结合仍然不清楚.
乙酸减少酶 (DHFR) 是细胞代谢中的关键酶,也是各种药物的点.

研究的目的:

研究与野生型和突变型DHFR结合的抑制剂的热力学和动力学.
阐明导致药物敏感性和耐药性的原子级机制.
开发一种更准确的药物蛋白相互作用理论模型.

主要方法:

使用分子动力学模拟来分析抑制剂结合.
使用马尔科夫状态建模来研究结合热力学和动力学.
研究了甲基酸盐 (MTX) 和其修饰形式与野生型和突变型DHFR的结合.

主要成果:

甲基 (MTX) 首选结合野生型DHFR的活性部位.
MTX的修改或DHFR的突变 (例如F31V) 导致活性部位的结合不稳定,并增加了对二次部位的结合.
确定了多个稳定的抑制剂结合状态,挑战了传统的两种状态结合模型.

结论:

药物敏感性变化与多种结合状态有关,而不仅仅是简单的 afinity 降低.
具有相对稳定的二次结合点的存在影响了药物的疗效.
这项研究为了解DHFR和其他潜在蛋白质的耐药性机制提供了一个新的理论框架.

更多相关视频

Determination of Protein-ligand Interactions Using Differential Scanning Fluorimetry

Determination of Protein-ligand Interactions Using Differential Scanning Fluorimetry

Published on: September 13, 2014

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

相关概念视频

Ligand Binding and Linkage

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...

Enzyme Inhibition

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.

Allosteric Proteins-ATCase

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...